Easy to perform
DVTect is easily placed on the calf without any discomfort. It is designed to be easier than Doppler ultrasound examination and minimal special skills are needed to operate the device.
A reliable screen
The best alternative clinical assessments for DVT have no greater accuracy than 60% [4]. Due to the current deficit in diagnostic clinical assessment for DVT and lack of tools to assist in this process, there is a need to develop reliable tools to aid specific, focussed assessment to detect early signs of DVT. DVTect has been designed to provide a reliable screening technology for DVT.
Non-invasive
DVTect is designed to be non-invasive with minimal inconvenience to the patient and simple to use by a clinician, nurse or technician. Developed for point-of-care use, DVTect allows daily convenient monitoring for DVT in high risk patients.
Inexpensive to carry out
By reducing the need for expensive ultrasound tests, DVTect is designed to deliver significant time, convenience and cost savings in hospital. It’s a cost-effective, easy way to screen for DVT.
[1] Ho WK, Hankey GJ, Eikelboom JW. The incidence of venous thromboembolism: a prospective, community‐based study in Perth, Western Australia. Med J Aust. 2008;189(3):144‐147
[2] Gross SD, et al., Thromb Res. 2016 Jan; 137: 3-10
[3] Australian Commission on Safety and Quality in Healthcare, 2018, Venous Thromboembolism Prevention Clinical Care Standard, Online available from:<https://www.safetyandquality.gov.au/wp-content/uploads/2018/10/D18-34197-VTE_Brochure_FINAL_WEB-VERSION.pdf>
[4] Wells, PS Advances in the diagnosis of venous thromboembolism. J. Thromb Thrombolysis, 2006. 21(1): p 31-40
About us
KYNETYKA TECHNOLOGIES PTY LTD
Kynetyka Technologies Pty Ltd (ACN 614 880 956) is an independent, privately-held Australian medical device company, headquartered in Melbourne, led by its directors; Craig Newton and Xenia Sango, with the aim of developing and commercialising the unique DVTect technology worldwide.
Meet Our Team
KNOWLEDGE & EXPERIENCE
